Analyst Price Targets — INVA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 26, 2026 2:24 pm | Steve Seedhouse | Cantor Fitzgerald | $32.00 | $23.98 | StreetInsider | Inova Technology, Inc. (INVA) PT Raised to $32 at Cantor Fitzgerald on Improved Outlook |
| February 17, 2026 11:10 am | — | BTIG | $35.00 | $22.70 | TheFly | Innoviva initiated with a Buy at BTIG |
| December 16, 2025 11:11 am | — | H.C. Wainwright | $46.00 | $20.15 | TheFly | Innoviva price target raised to $46 from $45 at H.C. Wainwright |
| September 30, 2025 9:12 am | — | Goldman Sachs | $17.00 | $19.03 | TheFly | Innoviva initiated with a Sell at Goldman Sachs |
| August 11, 2025 11:53 am | Trevor Allred | Oppenheimer | $35.00 | $19.93 | Benzinga | This Arm Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Monday |
| March 7, 2025 12:00 pm | — | Scotiabank | $55.00 | $17.64 | TheFly | Innoviva initiated with an Outperform at Scotiabank |
| August 8, 2022 9:38 am | — | Morgan Stanley | $13.00 | $14.72 | Benzinga | Morgan Stanley Maintains Underweight on Innoviva, Raises Price Target to $13 |
| July 15, 2022 11:05 am | — | Morgan Stanley | $12.00 | $14.37 | Benzinga | Morgan Stanley Maintains Underweight on Innoviva, Lowers Price Target to $12 |
Latest News for INVA
Innoviva, Inc. (INVA) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript
Innoviva, Inc. (NASDAQ: INVA - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eight ratings firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating on the
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today reported financial results for the fourth quarter and full year ended…
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in a fireside chat at the Oppenheimer…
SG Americas Securities LLC grew its position in shares of Innoviva, Inc. (NASDAQ: INVA) by 134.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 49,079 shares of the biotechnology company's stock after buying an additional 28,141 shares during the
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for INVA.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.